Antibody for Epstein-Barr virus, Pg18

Key Highlights:

• Scientists at the Fred Hutchinson Cancer Center developed human-like antibodies to block the Epstein-Barr virus (EBV).
• The antibody, named Pg18, prevents the virus from attaching to and entering immune cells.
• Pg18 completely prevented EBV infection in lab models with human immune systems.
• EBV is linked to certain cancers and chronic diseases, particularly in transplant patients.

Detailed Insights:

• The Epstein-Barr virus (EBV) is a common virus that infects most people, often with no symptoms, but can lead to cancers like lymphoma and nasopharyngeal carcinoma.
• Researchers engineered mice with human antibody genes to create Pg18, a human-like antibody that neutralizes EBV by blocking its entry into B cells.
• Transplant patients are particularly vulnerable to EBV reactivation due to immunosuppressive drugs, making this antibody a potential therapeutic intervention.
• This breakthrough offers a new approach to prevent and treat EBV-related diseases, addressing the challenge of the virus's ability to invade B cells.

Scientific/Technical Concepts Involved:

• Antibody: A protein produced by the body's immune system to neutralize foreign invaders like viruses.
• Epstein-Barr Virus (EBV): A herpes virus that can cause infectious mononucleosis and is associated with certain cancers.
• B Cells: A type of white blood cell that produces antibodies to fight infection.